Evidence map›Paper›PMID 42797409›Full record

ArticlePharmaceuticals (Basel, Switzerland)2026

Artificial Intelligence-Guided Prioritization and Experimental Evaluation of Synergistic Target Combinations for Breast Cancer Therapy.

Chunlai Feng, Qiuqi Feng, Shengnan She, Ruojing Yang, Mengru Li, Lu Gong, Mengjie Rui

Abstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chunlai FengSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.ORCID 0000-0002-9628-1331
Qiuqi FengSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Shengnan SheSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.ORCID 0009-0006-7110-1345
Ruojing YangSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Mengru LiSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Lu GongSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Mengjie RuiSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.ORCID 0000-0001-5566-817X

Funding

Drug Efficacy and Health Risk Assessment Key Laboratory of Zhenjiang SS2024006National Natural Science Foundation of China 82074286National Natural Science Foundation of China 82574882Open Fund Project of the NHC Key Laboratory of Diagnosis and Therapy of Gastrointestinal Tumor NHCDP2024005the Natural Science Foundation of Jiangsu Province BK20251851Zhenjiang Science and Technology Development Foundation SH2025069
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

artificial intelligencebreast cancerdrug synergyinhibitor combinationtarget combination

Identifiers

PMID42797409
PMCPMC13610653

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.